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patients: 48-week ﬁnal results of VEMAN studyS. Nozza1, L. Galli1, A. Antinori2, S. Chiappetta1,3, F. Mazzotta4, M. Zaccarelli2, S. Ottou2, D. De Battista5, M. Pogliaghi1,3,
M. Di Pietro4, M. Malnati5, M. Ripa1,3, S. Bonora6 and A. Lazzarin1,3, on behalf of VEMAN Study Group
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Transplantation and Infectious Diseases, San Raffaele Scientiﬁc Institute, Milan and 6) Unit of Infectious Diseases, Department of Medical Sciences,
University of Torino, ItalyAbstractNon-conventional strategies with nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimens in antiretroviral naive human
immunodeﬁciency virus (HIV) -infected patients have been explored in clinical trials. A prospective, open-label, randomized (1:1),
multicentre, proof-of-concept trial (VEMAN study, EUDRACT number 2008-006287-11) was conducted assigning HIV-infected naive
patients to once-daily maraviroc plus lopinavir/ritonavir (MVC group) or to tenofovir/emtricitabine plus lopinavir/ritonavir (TDF/FTC
group). Clinical and laboratory data were collected at baseline, and after 4, 12, 24, 36 and 48 weeks with the objective to evaluate the
48-week virological and immunological efﬁcacy. HIV-1 DNA load and CD4+ T-cell subsets were analysed on frozen peripheral blood
mononuclear cells collected at baseline, 4 and 48 weeks to explore the trend in HIV reservoirs. Fifty patients were randomized and
included in the analysis. During follow up, HIV-1 RNA decreased similarly in both groups and, at week 48, all patients in the MVC group
and 22/24 (96%) in the TDF/FTC group had < 50 copies/ml of HIV-1 RNA. CD4+ trend during follow up was higher in maraviroc-
treated patients (MVC group: 286 (183–343) versus TDF/FTC group: 199 (125–285); Mann–Whitney U-test: p 0.033). A signiﬁcant 48-
week increase of CCR5+ CD4+ T cells and CD4+ effector memory cells was observed among maraviroc-treated patients (Wilcoxon
signed rank test: p 0.016 and p 0.007, respectively). No signiﬁcant variations were found in naive and central memory CD4+ T cells.
Among naive patients with an R5 virus, treatment with maraviroc and lopinavir/ritonavir was shown to provide a virological response
compared to a triple therapy and a greater immunological beneﬁt.
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p://dx.doi.org/10.1016/j.cmi.2014.12.006IntroductionThe current recommended antiretroviral treatment for naive
human immunodeﬁciency virus 1 (HIV-1) -infected patients is a
combination of two nucleoside/nucleotide reverse transcriptase
inhibitors (NRTIs) and a third agent from another class [1].
Such triple therapies have demonstrated antiviral efﬁcacy;ious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Nozza et al. NRTI-sparing regimen for HIV infection 510.e2nevertheless, this type of therapeutic approach may be
hampered by drug toxicity. On the other hand, two fully active
antiretroviral drugs may be sufﬁcient to suppress HIV-1 repli-
cation in treatment-naive patients [2–4].
Maraviroc is a potent selective CCR5 antagonist approved
for the treatment of HIV-1 in both naive and experienced pa-
tients. Maraviroc could be an attractive option for treatment-
naive patients because of increasing evidence for its safe use
[5] and a high prevalence in this setting [6] of HIV-1 strains that
are CCR5 users. Efﬁcacy and pharmacokinetics data from
previous studies demonstrated the potency of MVC when given
as a 300 mg equivalent once daily dose [7]. Moreover in the
MOTIVATE study, when maraviroc was given either once or
twice daily in combination with boosted protease inhibitors,
both arms had favourable virological outcomes [7]. Some
available data about a novel strategy based on a dual therapy
with maraviroc plus protease inhibitors in naive HIV-1-infected
patients showed promising results [8].
The largest randomized trial with darunavir/ritonavir and
maraviroc 150 mg daily (A4001095, MODERN trial) was termi-
nated on 8 October 2013 following a preliminary review of the
week 48 primary efﬁcacy data by the study’s external independent
Data Monitoring Committee (DMC). TheDMC assessed the data
as demonstrating signiﬁcant differences between the treatment
arms in virological responses (72% in maraviroc group, 83% in
standard regimen) and failures. The DMC recommended and the
Sponsor concurred that the study be terminated because of the
inferior efﬁcacy of the maraviroc arm compared with the
comparator arm (emtricitabine/tenofovir) [9].
VEMAN (Virological Efﬁcacy of Maraviroc in Antiretroviral
Naive Patients) is a proof of concept study on adult, HIV-
infected and antiretroviral-naive patients (EUDRACT number
2008-006287-11) conducted with the aim to compare the
virological and immunological efﬁcacy of a dual therapy
including maraviroc plus lopinavir/ritonavir (MVC group) to a
triple therapy including tenofovir/emtricitabine and lopinavir/
ritonavir (TDF/FTC group).Material and methodsStudy population
Adult, treatment-naive, HIV-1 infected patients, CD4 count
100 cells/μL, HIV-RNA 1000 copies/mL were screened
using the Troﬁle assay (Monogram Biosciences, San Francisco,
CA, USA); only patients with CCR5 tropic virus were enrolled
and randomized to the study treatments.
Other inclusion criteria were: absence of primary resistance
mutations to any of the proposed components of the study
arms and absence of chronic hepatitis B co-infection.Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InStudy design
This was a proof-of-principle, multicentre, randomized, open-
label, active-controlled, parallel-group study conducted in four
Italian sites.
The study was approved by local ethics committees and all
participants signed informed consent; the registration
EUDRACT number was 2008-006287-11.
All eligible patients were randomized 1:1 using a comput-
erized random-number-generator program to receive mar-
aviroc 150 mg once daily plus lopinavir/ritonavir 400/100 mg
twice daily (MVC group) or tenofovir/emtricitabine plus lopi-
navir/ritonavir 400/100 mg twice daily (TDF/FTC group).
Authorized study centre personnel randomized the participants
via a password protected internet website. The randomization
system determined the treatment and provided a randomiza-
tion number to be used for each participant.
The primary endpoint was the 12-week change of HIV-1
RNA from baseline. Secondary endpoints, evaluated at weeks
12, 24, 36 and 48, were: the proportion of participants with
HIV-1 RNA <50 copies/mL; change from baseline in HIV-1
RNA; change from baseline of immunological parameters; and
change from baseline in all the considered safety parameters.
Study evaluations
Randomized participants underwent clinical and laboratory ex-
aminations at baseline, and at weeks 4, 12, 24, 36 and 48. Labo-
ratory tests included the evaluation of HIV-1 RNA, CD4+ and
CD8+ absolute cell counts and percentage, bonemarrow function
(white blood cells and platelet count, haemoglobin), aspartate
aminotransferase, alanine aminotransferase, creatine phosphoki-
nase, creatinine, fasting glucose and insulin, total cholesterol, high-
density and low-density lipoprotein-cholesterol, triglycerides.
HIV-1 DNA load and CD4+ T-cell subsets (CCR5+ cells,
naive, central and effector memory) were determined on
frozen peripheral blood mononuclear cells (PBMCs) collected
at baseline, week 4 and week 48.
Viral rebound was deﬁned as two subsequent consecutive
measurements of HIV-RNA >50 copies/mL.
Cytoﬂuorometric analysis and HIV-1 proviral DNA
determination
A multiparametric cytoﬂuorometric protocol of CD4 T-cell
immunostaining was performed using the following monoclonal
antibodies: CD45RA (clone ALB11) and CD8 (clone SFCI21-
Thy2D3) (Beckman Coulter, Brea, CA, USA); CD3 (clone SK7),
CD4 (clone RPA-T4), CD27 (clone M-T271), CCR7 (clone
150503) and CCR5 (clone 2D7/CCR5) monoclonal antibodies
(Becton Dickinson, Franklin Lakes, NJ, USA). LIVE/DEAD
ﬁxable Aqua dead cell stain kit was purchased from Invitrogen
(Life Science, Carlsbad, CA, USA).fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 510.e1–510.e9
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rested for 4 h at 37°C in a 5% CO2 incubator. Cells were
washed and resuspended in PBS (Lonza-BioWhittaker, Basel
Switzerland) and incubated with LIVE/DEAD ﬁxable Aqua dead
cell stain (Invitrogen) to assess their viability. After washing with
FACS Buffer (PBS containing 1% fetal bovine serum (Lonza-
BioWhittaker) and 0.01% sodium azide (Sigma, St Louis, MO,
USA)] the mix of ﬂuorochrome-conjugated antibodies was
added to the cell suspension and incubated for 30 min at 4°C.
After an additional washing, samples were acquired with Gallios
ﬂow cytometer (Beckman Coulter, Inc.) and analysed using
FLOWJO version 8.8.7 (Tree Star, Ashland, OR, USA).
Lymphocytes were gated on a forward scatter area versus
side scatter area using pseudo-colour dot plot and dead cells
were removed according to Aqua staining. CD8– CD4+ T cells
were identiﬁed within the CD3+ lymphocytes. Then, the
maturation markers (CD45RA, CCR7, CD27) were plotted on
the x-axis versus forward scatter area on y-axis and all positive
cells were gated. Boolean gating analysis identiﬁed eight pat-
terns by calculating every possible combination of the three
populations gated. The expression of CCR5 was evaluated
within the CD4+ T-cell population and within all maturation
subsets (naive: CD45RA+ CCR7+ CD27+; central memory:
CD45RA– CCR7+ CD27+; transitional memory: CD45RA–
CCR7– CD27+; effector memory CD45RA– CCR7– CD27–;
terminally differentiated CD45RA+ CCR7– CD27–).
CCR6+ T cells, T helper type 17 (Th17) phenotype
(CXCR3– CCR6+), Th1Th17 phenotype (CXCR3+ CCR6+)
were differentiated to evaluate reservoirs.
HIV-1 DNA was measured on dry pellets of Fycoll-Hypaque
puriﬁed PBMCs using a previously described in-house-
developed assay [10].
Statistical analysis
The sample size for this pilot trial was based primarily on
feasibility considerations. This pilot randomized controlled trial
will inform the estimates of effect sizes and variance for a larger
trial. Results were described as median (interquartile range) or
frequency (%), as appropriate. The primary analysis considered
the primary endpoint and was performed according to the
intention-to-treat principle, including all randomized subjects.
Changes were calculated within each treatment group and
signiﬁcant variations were assessed by the Wilcoxon signed
rank test.
Secondary analyses considered the secondary endpoints.
Values of continuous independent distributions were compared
by the non-parametric Mann–Whitney U-test.
Chi-square test or Fisher exact test was applied in relation to
categorical variables. The Spearman correlation coefﬁcient was
calculated to assess the relationship between continuousClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectvariables. Analysis of variance (ANOVA) for repeated measures
was also applied to detect differences between the two study
groups in changes through time and the Greenhouse–Geisser
probabilities were reported. A two-sided α level of 0.05 was
taken as reference to detect statistical signiﬁcance in all analyses.
The analyses were performed using SAS Software, release
9.2 (SAS Institute, Cary, NC, USA).ResultsSixty-seven patients with CD4 count 100 cells/μL and HIV-1
RNA  1000 copies/mL were included in the study and a
Troﬁle test was performed: 50/67 (75%) had CCR5 tropic virus
and were randomized: 26 in the MVC group and 24 in the TDF/
FTC group. Baseline demographic, clinical and immuno-
virological characteristics are shown in Table 1 and a ﬂow di-
agram of patients is given in Fig. 1.
Virological results
During the study, HIV-1 RNA showed a similar decrease in
both groups (Fig. 2a). At week 12 (primary endpoint), the
median HIV-1 RNA change in the MVC group was –2.86
(–3.19 to –2.49) log10 copies/mL and –2.45 (–3.06 to
–2.15) log10 copies/mL in the TDF/FTC group (Wilcoxon rank-
sum test: p 0.089). At week 48, the median change of HIV-1
RNA was –2.86 (–3.28 to –2.52) log10 copies/mL in the
MVC group and –2.78 (–3.14 to –2.22) log10 copies/mL in
TDF/FTC patients (Wilcoxon rank-sum test: p 0.262).
At week 48, all patients in the MVC group and 22/24 (96%)
in the TDF/FTC group had HIV RNA <50 copies/mL (difference
between proportions (MVC–TDF/FTC): +8.3%, 95% CI –4.5
to 8.3%; Fisher’s exact test: p 0.225).
We analysed the HIV-1 DNA load; overall, a substantial
decrease in HIV-1 DNA levels was observed: values dropped
from 1174 (645–1512) Geq/106 PBMC at baseline to 302
(172–500) Geq/106 PBMC at week 48 (Greenhouse–Geisser
probabilities by ANOVA for repeated measures: p 0.0001). No
signiﬁcant differences between the two study groups were
found when comparing the changes in HIV-1 DNA load during
follow-up (MVC group: from 1250 (738–1512) copies/106 at
baseline to 291 (174–399) copies/106 PBMC (Wilcoxon signed-
sum test: p 0.004); TDF/FTC group: from 1017
(645–1384) copies/106 at baseline to 413 (232–623) copies/
106 PBMC (Wilcoxon signed-sum test: p 0.004); Green-
house–Geisser probabilities by ANOVA for repeated measures: p
0.515). HIV DNA change was not related to CD4+ cell counts
and immunological subset, but it was related to HIV RNA
decrease at week 48 (MVC group: r = 0.297, p 0.405; TDF/FTC
group: r = 0.80, p 0.01).ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 510.e1–510.e9
TABLE 1. Baseline characteristics of the patients.
Baseline characteristics Overall (n [ 50) MVC plus LPV/r (n [ 26) TDF/FTC plus LPV/r (n [ 24) p value
Gender n (%)
Male 48 (96%) 25 (96.2%) 23 (95.8%) 0.999
Female 2 (4%) 1 (3.8%) 1 (4.2%)
Age at last visit (years) 39.1 (32.4–44) 38.9 (34.2–44) 39.4 (34.3–43.5) 0.961
Risk factors, n (%)
MSM 38 (76%) 19 (73.1%) 19 (79.2%) 0.745
Heterosexual 12 (24%) 7 (26.9%) 5 (20.8%)
HIV infection (years) 2.9 (0.8–5.3) 2.9 (0.6–7.2) 2.9 (0.9–4.6) 0.459
Nadir CD4+ (cells/mL) 266 (242–315) 269 (249–321) 263 (230–308) 0.547
CD4 (cells/mL) 295 (260–369) 292 (261–359) 297 (257–373) 0.676
CD4 % 18.8 (14.6–23) 19.5 (16.3–24.3) 18.8 (14.3–22.3) 0.756
CD4/CD8 0.33 (0.25–0.47) 0.35 (0.25–0.48) 0.33 (0.28–0.4) 0.793
HIV-RNA (log10 copies/ml) 4.41 (3.96–4.8) 4.42 (4.07–4.84) 4.41 (3.84–4.76) 0.420
AST (U/L) 23 (20–29) 26 (21–37) 23 (19–26) 0.033
ALT (U/L) 27 (21–38) 34 (21–61) 25 (20–30) 0.045
CPK (U/L) 98 (73–147) 114 (73–165) 114 (73–165) 0.214
Creatinine (mg/dL) 0.83 (0.77–0.95) 0.83 (0.78–0.98) 0.83 (0.77–0.95) 0.641
Cholesterol (mg/dL) 171 (145–200) 178 (149–204) 160 (144–194) 0.236
LDL cholesterol (mg/dL) 100 (82–129) 105 (86–140) 100 (82–128) 0.386
HDL cholesterol (mg/dL) 40 (35–50) 38 (36–53) 41 (35–47) 0.622
Triglycerides (mg/dL) 91 (64–143) 91 (64–126) 91 (66–128) 0.831
Glucose (mg/dL) 83 (77–91) 81 (75–89) 84 (78–91) 0.268
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPK, creatine phosphokinase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MSM men who have sex
with men; MVC plus LPV/r, maraviroc plus lopinavir/ritonavir; TDF/FTC plus LPV/r, tenofovir/emtricitabine plus lopinavir/ritonavir.
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Overall, CD4+ cell count signiﬁcantly improved during follow
up starting from 295 (260–369) cells/μL at baseline to 537
(454–671) cells/μL at week 48 (Wilcoxon signed-sum test: p
<0.0001). CD4+ trend during follow up was signiﬁcantly
different between the two groups (Greenhouse–Geisser
probabilities by ANOVA for repeated measures: p 0.046): 48-
week CD4+ change was higher in MVC group (286FIG. 1. Flow diagram of the patients. TDF/
FTC, tenofovir/emtricitabine; MVC, mar-
aviroc; LPV/r, lopinavir/ritonavir. Dashed line
represents TDF/FTC+LPV/r, continuous line
represents MVC+LPV/r.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and In(183–343) cells/μL) than TDF/FTC group (199
(125–285) cells/μL) (Wilcoxon rank-sum test: p 0.033; Fig. 2b).
Results on immunological parameters were almost un-
changed even after the exclusion of the two patients with HV-
RNA >50 copies/mL at week 48 (data not shown).
No differences between groups were observed for the 48-
week CD4 % change (MVC group: +7.6 (4.1–10.7) %; TDF/
FTC group: +8.5 (5.5–12) %; Wilcoxon signed-rank test: p
0.854] and CD4/CD8 ratio (MVC group: +0.26 (0.15–0.53);fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 510.e1–510.e9
FIG. 2. Virological results of the study (a). HIV RNA change from baseline to week 48 (a). Variation of CD4+ cells from baseline to the 48-week follow
up (b). Median values of CD4+ changes in patients. The continuous line represents patients treated with maraviroc plus lopinavir/ritonavir; the dashed
line depicts patients treated with tenofovir/emtricitabine. For both graphs, bars represent the ﬁrst and the third interquartiles.
510.e5 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMITDF/FTC group: +0.24 (0.18–0.32); Wilcoxon signed-rank
test: p 0.366).
As for CD4+ T-cell subpopulations (Fig. 3), at week 48 MVC
patients tended to have a higher fraction of CCR5+ CD4+ T
cells compared with the TDF/FTC group (Wilcoxon signed-
rank test: p 0.075), resulting in a signiﬁcantly different changeFIG. 3. CD4+ T cells immunological subsets. Variation during follow up in
CCR7+ CD27+, (c) central memory CD4+ cells (CD45RA– CCR7+CD27+) an
values reported on the y axes are expressed as % of the total CD4+ cells.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectat 48 weeks (MVC group: + 7.5% (–4.5 to 11); TDF/FTC group:
–5.4 (–15.1 to –0.5); Wilcoxon signed-rank test: p 0.016).
MVC patients were also found to have a higher 48-week change
of CD4+ effector memory cells (MVC group: +1.6% (0.7–4.8);
TDF/FTC group: –4.4 (–13.5 to –0.2); Wilcoxon signed-rank
test: p 0.001). No signiﬁcant changes during follow up werepercentage of (a) CCR5+ CD4+ cells, (b) naive CD4+ cells (CD45RA+
d (d) effector memory CD4+ cells (CD45RA– CCR7– CD27– cells). The
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 510.e1–510.e9
CMI Nozza et al. NRTI-sparing regimen for HIV infection 510.e6observed within each study group in relation to naive (Wil-
coxon signed-sum test: p 0.160 in MVC group; p 0.233 in TDF/
FTC group) and central memory (Wilcoxon signed-sum test: p
0.232 in MVC group; p 0.569 in TDF/FTC group) T-cell subsets
and no differences between the two groups were found when
comparing the 48-week variations of naive (Wilcoxon rank-sum
test: p 0.081) and central memory (Wilcoxon rank-sum test: p
0.177) CD4+ T-cell subsets.
No signiﬁcant changes were observed in terms of CCR6+ T
cells (MVC group: from 9.3% (6.7–11.8) to 6.1% (4.8–7.2);
TDF/FTC group: from 10.1% (6.7–14) to 4.4% (3.8–6); Wil-
coxon signed-rank test: p 0.440), Th1Th17 (MVC group: from
3.7% (2–4.9) to 2.9% (1.8–3.9); TDF/FTC group: from 3.7%
(2.1–4.3) to 3.9% (2.3–4.6); Wilcoxon signed-rank test: p
0.576) and Th17 T cells (MVC group: from 3.5% (2.3–4.7) to
3.5% (2–4.2); TDF/FTC group: from 4.5% (3.6–4.7) to 2%
(1.7–2.8); Wilcoxon signed-rank test: p 0.407) between
different groups of treatment, although a signiﬁcant decrease of
CCR6+ (p 0.002), Th1 (p 0.042) and Th17 (p 0.01) was
observed overall.
The CD4+ cell increase was related to HIV reservoirs
(Fig. 4): CCR6+ T cells (r = 0.75, p 0002), Th1Th17 cellsFIG. 4. Correlation between CD4+ cells and HIV reservoirs: CCR6+ (a), T h
tenofovir/emtricitabine plus lopinavir/ritonavir group (TDF/FTC+LPV/r), c
(MVC+LPV/r).
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and In(r = 0.68, p 0.0012) and Th17 cells (r = 0.75, p 0.002), but was
not related to Th1 cells (r = –0.041, p 0.867).
Safety results
Five patients stopped treatment (two in the MVC group and
three in the TDF/FTC group) at week 24 for diarrhoea when
viral load was undetectable (HIV RNA<50 copies/mL).
Treatment was well tolerated and trends of bone marrow
function, aspartate aminotransferase, alanine aminotransferase
and creatine phosphokinase values, creatinine, glucose proﬁle
and lipid proﬁle during follow up were not clinically signiﬁcantly
different between the two groups.DiscussionThe VEMAN study showed a high rate of virological response in
HIV-1-infected patients naive to antiretroviral therapy treated
with dual therapy containing lopinavir/ritonavir and maraviroc
150 mg once daily and similar to that observed in patients
treated with a conventional triple therapy. In clinical practice,
the development of dual therapies based on the use of aelper type 1 (Th1) (b), Th1Th17 (c), Th17 (d). Dashed line represents
ontinuous line represents maraviroc plus lopinavir/ritonavir group
fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 510.e1–510.e9
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represent an alternative to traditional regimens for long-term
management. Indeed, the drug toxicities associated with
NRTIs and non-NRTIs [11] regimens and the emergence of
resistance mutations [12] represent two critical points for the
long-term clinical management of HIV-1-infected individuals.
Maraviroc 150 mg once daily plus protease inhibitor/rito-
navir was evaluated in other studies: in combination with ata-
zanavir/ritonavir (A4001078) [6] and in combination with
darunavir/ritonavir (MIDAS) [13]. Lopinavir/ritonavir was cho-
sen because it was in the ﬁrst-line regimen in Italy when the
study was designed [14]. At week 48, 75% and 92% of patients,
respectively, had HIV RNA <50 copies/mL. All three studies,
A4001078, MIDAS and VEMAN, performed pharmacological
analyses that suggested that once-daily 150 mg dosing of mar-
aviroc was pharmacologically adequate in association with
protease inhibitor/ritonavir in treatment-naive subjects. In
particular, in our study ten male patients were included in the
analysis: results were previously published [15]. In summary, all
patients showed a maraviroc average concentration >75 ng/mL,
and lopinavir and ritonavir exposure levels were not affected by
the co-administration of maraviroc.
The average maraviroc plasma concentration of 75 ng/mL is
associated with maximum virological efﬁcacy, but this
measuring is not practical in the clinical setting. The minimum
effective concentration has not yet been deﬁned. For this
reason, some available data suggest the use of maraviroc
300 mg once daily in association with a boosted protease in-
hibitor in the clinical setting, in particular with darunavir/rito-
navir once daily [16]. This dosage is well tolerated and has a
favourable pharmacokinetic proﬁle.
A large, phase III, randomized trial with maraviroc 150 mg
daily plus darunavir/ritonavir in naive patients (MODERN trial,
A4001095, NTC01345630) was discontinued for the minor
virological efﬁcacy of the study group [9]. It was a randomized
trial with 797 subjects enrolled (396 in the MVC group and 401
in the TDF/FTC group) At week 48, 77.3% in the MVC group
and 86.8% in the TDF/FTC group achieved undetectable viral
load; in a subgroup of patients with baseline HIV RNA
>100 000 copies/mL only 65.4% of the MVC group achieved
undetectability. Higher baseline viral load is associated with
lower response in other dual therapy strategies (such as ral-
tegravir plus darunavir/ritonavir). In our small study, only 4/50
(4%) of enrolled patients had baseline HIV RNA
>100 000 copies/mL (two randomized in the MVC group and
two in the TDF/FTC group), which could explain the high rate
of virological response.
The HIV reservoir, measured with HIV DNA, decreased
during active highly active antiretroviral therapy [17]; the effect
of maraviroc on the circulating PBMC reservoir was signiﬁcantClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectin the small group of naive patients studied, although no dif-
ferences with respect to conventional therapy with tenofovir/
emtricitabine were found.
A subset population of CD4+ cells, CCR6+ cells, was
considered as HIV reservoirs, based on previous data [18].
These cells harboured higher levels of HIVDNA integrated.
The increase in CD4+ cells observed during antiretroviral
therapy was associated with decrease of CCR6+ cells, both
Th1Th17 and Th17 phenotypes. CCR6 was recently identiﬁed
as an HIV co-receptor that inﬂuences migration of memory
CD4+ cells and contributes to viral dissemination [19]; in
particular ligands to CCR6 on Th1 and Th17 cells inhibits the
viral infection [20]. In our study, efﬁcacious antiretroviral
therapy decreases CCR6+ T cells and HIV DNA during ﬁrst 48
weeks of treatment, suggesting a decreasing role of highly active
antiretroviral therapy in reservoirs.
Larger cohorts of patients and longer follow up are needed
to fully explore this issue.
Patients treated with maraviroc plus lopinavir/ritonavir
showed a greater increase in CD4+ cell counts; this result is
consistent with a similar immunological recovery observed with
other regimens containing maraviroc, both in naive and expe-
rienced subjects [21,22]. The MOTIVATE trial showed a
greater CD4 gain in experienced patients treated with mar-
aviroc (113 cells/mL after 96 weeks) [7]. In the clinical setting
we studied a small cohort of 28 patients that increased to
211 cells/mL after 96 weeks of successfully therapy containing
maraviroc [22]. This effect on the immune system could be
differentiated between thymic output and peripheral extra-
thymic expansion [23].
The analysis of the CD4+ cell subsets revealed better
maraviroc-induced immune recovery. It was not associated
with an expansion of both naive and central memory cells, but
with a signiﬁcant increase of effector memory cells. Increasing
number of naive and central memory cells is suggestive of
improved immune regenerative capacity [24]; in the contrast,
the observed preferential expansion of the effector/memory
CD4 populations suggest that the immune recovery observed
in the peripheral blood is mainly due to either a better survival/
proliferation of experienced CD4 cells or a different redistri-
bution between lymphoid tissues and the circulating pool of
CD4 T cells.
Greater CCR5 expression was observed in the MVC group,
which is consistent with other antiretroviral therapy combi-
nations containing maraviroc [25]; the greater expression of
CCR5 on CD4+ cells might indicate a selective sparing/tissue
distribution of activated CD4 cells that represent a preferential
cell-target for HIV-1 infection. This phenomenon might
contribute to prevent the switch of co-receptor usage from
CCR5 to CXCR4, an important step toward the progression ofious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 510.e1–510.e9
CMI Nozza et al. NRTI-sparing regimen for HIV infection 510.e8HIV infection [26] and virological failure. Use of maraviroc
could increase CCR5+ CD4+ cells, with possible prevention of
overgrowth of CXCR4-tropic viral strains by allowing for a less
favourable substrate in which to replicate.
The treatment was well tolerated and it was not associated
with elevations in cholesterol or triglycerides as expected for
the proﬁle drug [27]. We did not observe a signiﬁcant differ-
ence with triple therapy, although the NRTI-sparing regimen
could preserve patients from long-term toxicities.
VEMAN is a proof of principle study, with a small sample
size; as a result, although the study was not powered to high-
light statistical differences, the virological efﬁcacy and safety
seemed to be similar in the two study groups and these results
are better than other small studies with NRTI-sparing regimens
containing maraviroc. In addition, such dual therapy was asso-
ciated with a greater increase in CD4+ cell count, with increase
of CCR5+ CD4+ cells, that have a protective role in emerging
CXCR4 virus and inﬂammatory phenomena. Due to small
sample size, this strategy could be considered in some cases,
such as for patients with baseline HIV RNA <100 000 copies/
mL and who cannot take NRTIs for safety reasons.Transparency declarationFunding: The study was partially supported by ViiV Healthcare.
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